PharmaEssentia Future Growth

Future criteria checks 5/6

PharmaEssentia is forecast to grow earnings and revenue by 109% and 34.2% per annum respectively. EPS is expected to grow by 108.7% per annum. Return on equity is forecast to be 14.6% in 3 years.

Key information

109.0%

Earnings growth rate

108.7%

EPS growth rate

Biotechs earnings growth	37.2%
Revenue growth rate	34.2%
Future return on equity	14.6%
Analyst coverage	Low
Last updated	19 Mar 2024

Recent future growth updates

Recent updates

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Nov 30

Earnings and Revenue Growth Forecasts

TWSE:6446 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	15,222	N/A	N/A	N/A	1
12/31/2025	12,407	4,839	1,778	4,624	3
12/31/2024	8,390	2,051	-735	821	3
12/31/2023	5,106	-624	-2,033	-706	N/A
9/30/2023	4,300	-890	-1,867	-1,113	N/A
6/30/2023	3,805	-1,498	-2,318	-1,549	N/A
3/31/2023	3,518	-1,569	-2,063	-1,436	N/A
12/31/2022	2,882	-1,375	-1,826	-1,505	N/A
9/30/2022	2,420	-2,111	-1,822	-1,572	N/A
6/30/2022	1,702	-2,403	-2,160	-2,068	N/A
3/31/2022	811	-2,669	-2,597	-2,531	N/A
12/31/2021	657	-2,811	-2,560	-2,462	N/A
9/30/2021	569	-2,756	-2,814	-2,657	N/A
6/30/2021	610	-2,673	-2,643	-2,440	N/A
3/31/2021	654	-2,340	-2,215	-2,019	N/A
12/31/2020	557	-1,948	-1,663	-1,455	N/A
9/30/2020	464	-1,204	-1,266	-1,020	N/A
6/30/2020	332	-862	-1,053	-845	N/A
3/31/2020	271	-856	-1,077	-844	N/A
12/31/2019	306	-843	-1,151	-945	N/A
9/30/2019	130	-1,113	-978	-836	N/A
6/30/2019	129	-1,080	-1,099	-919	N/A
3/31/2019	61	-1,086	-1,067	-899	N/A
12/31/2018	26	-1,040	-978	-827	N/A
9/30/2018	4	-930	-940	-823	N/A
6/30/2018	4	-882	-820	-749	N/A
3/31/2018	4	-878	-790	-755	N/A
12/31/2017	4	-872	-819	-790	N/A
9/30/2017	4	-862	N/A	-750	N/A
6/30/2017	5	-898	N/A	-762	N/A
3/31/2017	6	-904	N/A	-696	N/A
12/31/2016	5	-845	N/A	-657	N/A
9/30/2016	7	-892	N/A	-685	N/A
6/30/2016	9	-865	N/A	-628	N/A
3/31/2016	11	-870	N/A	-579	N/A
12/31/2015	12	-853	N/A	-527	N/A
9/30/2015	9	-819	N/A	-556	N/A
6/30/2015	9	-804	N/A	-567	N/A
3/31/2015	9	-796	N/A	-601	N/A
12/31/2014	13	-853	N/A	-599	N/A
9/30/2014	17	-812	N/A	-470	N/A
6/30/2014	19	-833	N/A	-448	N/A
3/31/2014	46	-713	N/A	-367	N/A
12/31/2013	72	-593	N/A	-285	N/A
9/30/2013	81	-449	N/A	-240	N/A
6/30/2013	89	-305	N/A	-195	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6446 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 6446 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 6446 is expected to become profitable in the next 3 years.

Revenue vs Market: 6446's revenue (34.2% per year) is forecast to grow faster than the TW market (10.6% per year).

High Growth Revenue: 6446's revenue (34.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 6446's Return on Equity is forecast to be low in 3 years time (14.6%).

PharmaEssentia Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Forecast breakeven date moved forward to 2023

Price target increased by 32% to NT$585

Price target increased to NT$443

Price target increased to NT$357

Consensus revenue estimates fall by 29%

Forecast to breakeven in 2023

Recent updates

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

Forecast breakeven date moved forward to 2023

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Price target increased by 32% to NT$585

Full year 2022 earnings: EPS exceeds analyst expectations

PharmaEssentia Corporation Submits New Drug Registration of BESREMi for PV in Malaysia

PharmaEssentia Corporation Announcement of Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Third quarter 2022 earnings: EPS misses analyst expectations

Price target increased to NT$443

Less than half of directors are independent

AOP Files Civil Action Against the PharmaEssentia Corporation in Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Receives "Prior Authorization for Import of Medicines" for Besremi In Macau

Taiwan Ministry of Health and Welfare Approves the Pharmaceutical Plant with GMP to Athenex for KX01 (Tirbanibulin) in the U.S

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

PharmaEssentia Corporation Announces Approval of New Drug Application (Nda) of Kx01 for Actinic Keratosis (Ak) in Taiwan

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

PharmaEssentia Corporation Announces Appointment of Lih-Ling Lin as Chief Scientific Officer

PharmaEssentia Corporation Announces Preliminary Results of the Phase II Clinical Trial of Ropeginterferon Alfa-2B(P1101) for the Treatment of PV in China

PharmaEssentia Corporation Announces Submission of Application to TFDA for Change of Study Purpose from IIT to Company-Sponsored Clinical Trial for Treatment of Covid-19 by Ropeginterferon Alfa-2B

PharmaEssentia Corporation Receives Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia(ET)

PharmaEssentia Corporation's Subsidiary PharmaEssentia USA Corporation Appoints Meredith Manning to President of the Americas

Price target increased to NT$357

Less than half of directors are independent

PharmaEssentia Corporation announced a financing transaction

Consensus revenue estimates fall by 29%

PharmaEssentia Corporation, Annual General Meeting, May 27, 2022

Forecast to breakeven in 2023

Consensus forecasts updated

German Federal Court of Justice Upholds AOP's License Rights in Ropeginterferon and PEC's Liability for Damages

Third quarter 2021 earnings released: NT$2.70 loss per share (vs NT$2.42 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: NT$2.08 loss per share (vs NT$0.92 loss in 2Q 2020)

Consensus revenue estimates fall to NT$568.0m

Price target decreased to NT$98.00

First quarter 2021 earnings released: NT$2.63 loss per share (vs NT$1.30 loss in 1Q 2020)

AOP Orphan Reports Full Validity of Arbitral Award Against PharmaEssentia

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation Announces Complete Response Letter for the Drug BESREMi® by US Food & Drug Administration

PharmaEssentia Corporation Provides U.S. Regulatory Update on Ropeginterferon Alfa-2B-Njft for the Treatment of Polycythemia Vera

Analysts lower revenue estimates to NT$1.62b

Price target raised to NT$110

PharmaEssentia Corporation, Annual General Meeting, May 26, 2021

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Full year 2020 earnings released: NT$8.04 loss per share (vs NT$3.85 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Analysts lower revenue estimates to NT$1.82b

New 90-day high: NT$103

PharmaEssentia (GTSM:6446) Is Using Debt Safely

PharmaEssentia Initiates Pivotal Trial of Ropeginterferon Alfa-2B to Treat Essential Thrombocythemia

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

PharmaEssentia Corporation Five-Year Data on Ropeginterferon Alfa-2b Illustrate Durable Response at Five Years in People With Polycythemia Vera

PharmaEssentia Corporation's (GTSM:6446) Profit Outlook

Third quarter 2020 earnings released: NT$2.42 loss per share